Weill Cornell Medical College researchers seek participants with PTSD for a Phase II Clinical Trial which will test a novel pharmacotherapy for PTSD. Participants will receive both the medication, SRX246, for 8 weeks and 8 weeks of placebo. Participants will be assessed at baseline and then...